女性健康与肾脏保护药物。
Women's health and kidney protective medications.
机构信息
Department of Nephrology, Institute of Nephro-Urology, Bengaluru, Karnataka, India.
Division of Nephrology, Baylor College of Medicine, Houston, Texas.
出版信息
Curr Opin Nephrol Hypertens. 2024 Sep 1;33(5):486-493. doi: 10.1097/MNH.0000000000001000. Epub 2024 May 3.
PURPOSE OF REVIEW
We discuss the sex-based differences in the pharmacokinetics and pharmacodynamics of kidney protective medications and their implications on women's health.
RECENT FINDINGS
A critical examination of adverse drug reactions highlights the underrepresentation of women in clinical trials for kidney and cardiovascular protective drugs, such as SGLT2 inhibitors, ACE inhibitors, and endothelin receptor antagonists. This underscores the need for sex-specific analyses in clinical studies to accurately assess medication efficacy and safety.
SUMMARY
The research demonstrates that women are more likely to experience adverse events and less likely to benefit from certain treatments, emphasizing the urgent need for healthcare providers to adopt a sex-informed approach in prescribing practices. Future research should prioritize sex differences from the outset to enhance understanding and improve clinical outcomes for women with chronic kidney disease and cardiovascular conditions.
目的综述
我们讨论了肾保护药物在药代动力学和药效学方面的性别差异及其对女性健康的影响。
最近的发现
对药物不良反应的批判性研究强调了女性在肾和心血管保护药物（如 SGLT2 抑制剂、ACE 抑制剂和内皮素受体拮抗剂）临床试验中的代表性不足。这凸显了在临床研究中进行性别特异性分析以准确评估药物疗效和安全性的必要性。
总结
研究表明，女性更有可能出现不良反应，且从某些治疗中获益的可能性较小，这强调了医疗保健提供者在开处方时采用性别知情方法的迫切需要。未来的研究应从一开始就优先考虑性别差异，以增强对慢性肾脏病和心血管疾病女性的理解，并改善其临床结局。
Zotero 插件